ABAriane Bour

Ariane Bour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ariane Bour has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Photomyogenic response in Niemann–Pick type C: a case report

    by A. Bour, J. Nicolai, H. van Schrojenstein Lantman-De Valk, V. van Kranen-Mastenbroek


  • Depressive symptoms and executive functioning in stroke patients: a follow‐up study

    by A. Bour, S. Rasquin, M. Limburg, F. Verhey

    Background: Cognitive and emotional sequellae are commonly observed in stroke patients and these symptoms often co‐occur. Diagnosis can be difficult since symptoms of depression and executive dysfunction overlap.Objective: To study the longitudinal relationship between depressive symptoms and executive dysfunction in stroke patients.Methods: The study comprises of 116 first‐ever stroke patients who were followed‐up for 2 years and who were assessed for emotional and cognitive sequellae after 1, 6, 12, and 24 months. Emotional disturbances were evaluated using the SCL‐90 depression subscale. Executive functions were assessed using compound scores of a combination of the interference scores of the Stroop Colour Word Test and the Concept Shifting Test.Results: Twenty‐five patients suffered from both depressive symptoms and executive dysfunction, 28 patients were depressed with no signs of executive dysfunction, and 13 patients showed executive dysfunction with no depressive symptoms. Patients with executive dysfunction had higher mean SCL‐90‐D scores compared to patients with no executive dysfunction (30.9 (SD 11.7) versus 26.2 (SD 11.1, p = 0.037). Depressive symptoms were predictive for executive dysfunction in a regression analysis corrected for age, sex, and diabetes mellitus but not after additional correction for pre‐existent brain damage and other vascular risk factors. After 2 years 66.6 and 53.3% of patients with both depressive symptoms and executive dysfunction at baseline still had depressive symptoms and executive dysfunctions respectively and had worse prognostic outcome than patients with depressive symptoms or executive dysfunction alone.Conclusions: Symptoms of depression and executive dysfunction are highly prevalent in stroke patients and often co‐occur. These patients are more at risk for poor stroke outcome, chronic depression, and cognitive deterioration. Copyright © 2010 John Wiley & Sons, Ltd.


  • The Effect of the APOE-ε4 Allele and ACE-I/D Polymorphism on Cognition during a Two-Year Follow-Up in First-Ever Stroke Patients

    by A.M.J.J. Bour, S.M.C. Rasquin, L. Baars, M.P.J. van Boxtel, P.J. Visser, M. Limburg, F.R.J. Verhey

    Background: Cognitive impairment is commonly observed after stroke and has a negative impact on survival and rehabilitation. Some stroke patients deteriorate in cognitive functioning whereas others do not. Environmental and demographic risk factors cannot fully explain this. There is growing evidence that a genetic predisposition plays a role in the pathogenesis of post-stroke cognitive decline. Objective: To study the influence of the APOE-Ε4 allele and the ACE-I/D polymorphism on cognitive functioning after stroke. Methods: We included 194 first-ever stroke patients of whom information about APOE genotyping and ACE-I/D polymorphism was available in 92 and 129 patients, respectively. Patients were cognitively assessed at 1, 6, 12 and 24 months after the event. Linear mixed models with slope estimates were used to study the influence of the APOE-Ε4 allele and the ACE-I/D polymorphism on the MMSE score, CAMCOG, executive functioning, psychomotor speed, and verbal memory function during follow-up. Results: Patients carrying the APOE-Ε4 allele more often suffered a lacunar infarction than non-carriers. The APOE-Ε4 allele had no effect on cognitive functioning during the follow-up. ACE-DD homozygosity was associated with a worse performance in executive functioning compared to patients with neither an APOE-Ε4 allele nor the ACE-DD genotype. There was no interaction between the APOE-Ε4 allele and the ACE-DD phenotype in the prediction of cognitive decline. Conclusion: The ACE-DD genotype may be associated with post-stroke cognitive decline while the APOE-Ε4 allele is not. Further research is needed to examine the role of genetic risk factors for post-stroke cognitive decline and to determine why some patients deteriorate cognitively after stroke but others do not.


  • Open Access

    A one-year follow-up study into the course of depression after stroke

    by A. Bour, S. Rasquin, I. Aben, A. Boreas, M. Limburg, F. Verhey


  • Open Access

    How predictive is the MMSE for cognitive performance after stroke?

    by Ariane Bour, Sascha Rasquin, Anita Boreas, Martien Limburg, Frans Verhey

    Cognitive deficits are commonly observed in stroke patients. Neuropsychological testing is time-consuming and not easy to administer after hospital discharge. Standardised screening measures are desirable. The Mini-Mental State Examination (MMSE) is the test most widely applied to screen for cognitive deficits. Despite its broad use, its predictive characteristics after stroke have not been exhaustively investigated. The aim of this study was to determine whether the MMSE is able to adequately screen for cognitive impairment and dementia after stroke and whether or not the MMSE can predict further deterioration or recovery in cognitive function over time. To this end, we studied 194 first-ever stroke patients without pre-stroke cognitive deterioration who underwent MMSEs and neuropsychological test batteries at 1, 6, 12, and 24 months after stroke. The MMSE score 1 month after stroke predicted cognitive functioning at later follow-up visits. It could not predict deterioration or improvement in cognitive functioning over time. The cut-off score in the screening for 1 cognitive disturbed domain was 27/28 with a sensitivity of 0.72. The cut-off score in the screening for at least 4 impaired domains and dementia were 26/27 and 23/24 with a sensitivity of 0.82 and 0.96, respectively. The results indicated that the MMSE has modest qualities in screening for mild cognitive disturbances and is adequate in screening for moderate cognitive deficits or dementia in stroke patients 1 month after stroke. Poor performance on the MMSE is predictive for cognitive impairment in the long term. However, it cannot be used to predict further cognitive deterioration or improvement over time.